Patents by Inventor Alexander J. Bridges
Alexander J. Bridges has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230287052Abstract: Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas-or TRAIL-mediated apoptosis.Type: ApplicationFiled: January 24, 2023Publication date: September 14, 2023Inventors: Cagri G. BESIRLI, Alexander J. BRIDGES, John K. FRESHLEY, William A. HUNKE, Linda L. JOHNSON, Francis X. SMITH, Ethan SYLVAIN, David N. ZACKS
-
Patent number: 11597749Abstract: Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.Type: GrantFiled: October 6, 2020Date of Patent: March 7, 2023Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ONL THERAPEUTICS, INC.Inventors: Cagri G. Besirli, Alexander J. Bridges, John K. Freshley, William A. Hunke, Linda L. Johnson, Francis X. Smith, Ethan Sylvain, David N. Zacks
-
Publication number: 20210094985Abstract: Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.Type: ApplicationFiled: October 6, 2020Publication date: April 1, 2021Inventors: Cagri G. BESIRLI, Alexander J. BRIDGES, John K. FRESHLEY, William A. HUNKE, Linda L. JOHNSON, Francis X. Smith, Ethan SYLVAIN, David N. ZACKS
-
Patent number: 10829518Abstract: Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.Type: GrantFiled: November 4, 2019Date of Patent: November 10, 2020Assignees: ONL THERAPEUTICS. INC., THE REGENT OF THE UNIVERSITY OF MICHIGANInventors: Cagri G. Besirli, Alexander J. Bridges, John K. Freshley, William A. Hunke, Linda L. Johnson, Francis X. Smith, Ethan Sylvain, David N. Zacks
-
Publication number: 20200123201Abstract: Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.Type: ApplicationFiled: November 4, 2019Publication date: April 23, 2020Applicants: ONL Therapeutics, Inc., The Regents of the University of MichiganInventors: Cagri G. BESIRLI, Alexander J. BRIDGES, John K. FRESHLEY, William A. HUNKE, Linda L. JOHNSON, Francis X. SMITH, Ethan SYLVAIN, David N. ZACKS
-
Patent number: 10508134Abstract: Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.Type: GrantFiled: April 29, 2016Date of Patent: December 17, 2019Assignees: ONL Therapeutics, Inc., The Regents Of The University of MichiganInventors: Cagri G. Besirli, Alexander J. Bridges, John K. Freshley, William A. Hunke, Linda L. Johnson, Francis X. Smith, Ethan Sylvain, David N. Zacks
-
Publication number: 20190201500Abstract: Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis. Also, described are compositions and methods for preventing, treating or ameliorating an inflammation-mediated and/or complement-mediated disease or condition in a subject comprising administering to the subject a Fas inhibitor, its derivative, a pharmaceutically acceptable salt thereof, of a gene therapy encoding the Fas inhibitor in an amount effective to inhibit Fas signaling.Type: ApplicationFiled: March 20, 2019Publication date: July 4, 2019Inventors: David Zacks, Andrew Kocab, John Freshley, Meredith Gregory-Ksander, Anitha Krishnan, Jana van de Goor, Alexander J. Bridges
-
Publication number: 20180291062Abstract: Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.Type: ApplicationFiled: April 29, 2016Publication date: October 11, 2018Applicants: ONL Therapeutics, Inc., The Regents of the University of MichiganInventors: Cagri G. BESIRLI, Alexander J. BRIDGES, John K. FRESHLEY, William A. HUNKE, Linda L. JOHNSON, Francis X. SMITH, Ethan SYLVAIN, David N. ZACKS
-
Patent number: 7067538Abstract: The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.Type: GrantFiled: May 21, 2003Date of Patent: June 27, 2006Assignee: Warner-Lambert Company, LLCInventors: Larry D. Bratton, Alexander J. Bridges, David T. Connor, Steven R. Miller, Yuntao Song, Kuai-Lin Sun, Bharat K. Trivedi, Paul C. Unangst
-
Patent number: 6469004Abstract: The invention provides compounds having formula (I), wherein W is OH, or derivatives of the carboxylic acid, and Q is a heterocyclo-condensed ortho-phenylene residue. These compounds are useful as MEK inhibitors, particularly in the treatment of proliferative diseases such as cancer.Type: GrantFiled: July 11, 2001Date of Patent: October 22, 2002Assignee: Warner-Lambert CompanyInventors: Stephen Barrett, Haile Tecle, Alexander J. Bridges
-
Patent number: 5525625Abstract: 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran inhibits MEK and, as such, is effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.Type: GrantFiled: January 24, 1995Date of Patent: June 11, 1996Assignee: Warner-Lambert CompanyInventors: Alexander J. Bridges, Alan R. Saltiel
-
Patent number: 4962194Abstract: A processing for preparing 5'-N,6-disubstituted adenosines from inosines. The adenosines have usefulness as neuroleptics, analgesics, cardiotonics, antihypertensives, antilipolytics, antihyperlipaemics, antiinflammatory agents, antithrombotic or antiembolic agents.Type: GrantFiled: October 19, 1988Date of Patent: October 9, 1990Assignee: Warner-Lambert CompanyInventor: Alexander J. Bridges
-
Patent number: 4933335Abstract: A novel series of quinolone carboxylic acids for use as antibacterial agents are described. Methods for making the compounds, methods of using the compounds and compositions containing them are also described. Certain novel intermediates are also described.Type: GrantFiled: October 13, 1988Date of Patent: June 12, 1990Assignee: Warner-Lambert CompanyInventors: Alexander J. Bridges, John M. Domagala
-
Patent number: 4803205Abstract: A novel series of quinolone carboxylic acids for use as antibacterial agents are described. Methods for making the compounds, methods of using the compounds and compositions containing them are also described. Certain novel intermediates are also described.Type: GrantFiled: June 7, 1988Date of Patent: February 7, 1989Assignee: Warner-Lambert CompanyInventors: Alexander J. Bridges, John M. Domagala
-
Patent number: 4780468Abstract: A novel series of quinolone carboxylic acids for use as antibacterial agents are described. Methods for making the compounds, methods of using the compounds and compositions containing them are also described. Certain novel intermediates are also described.Type: GrantFiled: August 7, 1987Date of Patent: October 25, 1988Assignee: Warner-Lambert CompanyInventors: Alexander J. Bridges, John M. Domagala
-
Patent number: 4755594Abstract: The present inventions are novel N.sup.6 -substituted adenosines wherein the N substituent is ##STR1## wherein Ar is an unsubstituted or substituted (1) phenyl, (2) 1- or 2-naphthalenyl, (3) 2- or 3-thienyl, (4) 2- or 3-furanyl, (5) 2-, 4-, or 5-thiazyl, (6) 2-, 3-, or 4-pyridyl, or (7) 2-pyrimidyl wherein the substituents include at least one of lower alkyl, halo, trifluoromethyl, hydroxy, lower alkoxy, lower acyloxyamino, N-lower monoalkyl or N,N-lower dialkylamino, lower thioalkyl, lower alkylsulfonyl, or nitro and R' is hydrogen or alkyl, A is ##STR2## wherein q, q', or q" are one to four, n and m are independently zero to three provided if A is a bond then n and m is at least 2 and if A is other than a bond then n and m is at least one. These novel adenosines have highly desirable central nervous system and cardiovascular activities and therefore the present invention also includes pharmaceutical compositions and methods of use therefor.Type: GrantFiled: December 9, 1986Date of Patent: July 5, 1988Assignee: Warner-Lambert CompanyInventors: Alexander J. Bridges, Harriet W. Hamilton, Walter H. Moos, Deedee L. Szotek